Structure Therapeutics

ANPA-0073 Clin1 cardiopulmonary diseases; LTSE-2578 Clin0 pulmonary fibrosis; undisclosed RD diabetes (2), obesity

Structure Therapeutics is creating life-changing medicines for patients by targeting G-protein coupled receptors (GPCRs) using advanced computational and structure-based technology. GPCRs are a large protein family of membrane proteins whose functional range from metabolism, immune system regulation to sensory system control. While there are several drugs already targeting GPCRs, StructureTx is exploring the remaining family members as clinical targets. StructureTx’s platform involves use of their structure-based technology to visualize receptor-binding interactions to design molecules with ideal properties to elicit precise downstream targeting. StructureTx’s clinical stage pipeline is currently focused on chronic diseases with unmet need.